Zydus Lifesciences and Torrent Pharma to Co-Market Semaglutide Injection in India
Ahmedabad, March 18, 2026 – Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited have entered into a licensing and supply agreement to co-market Semaglutide Injection in the Indian market.Under the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has secured semi-exclusive rights to co-market the product in India under its brand name SEMBOLIC TM. Zydus will market the product under its brands SEMAGLYN TM, MASHEMA TM, and ALTERME TM. Torrent Pharma will pay an upfront licensing fee to Zydus.Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered...